Quralis
  • Home
  • About Us
    • Our Team
    • Founders
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Precision Therapies
    • Therapeutic Programs
    • QurAlis Technology
    • Therapeutic Targets
    • Biomarkers
  • News
  • Investors
  • Contact Us
    • Careers
Quralis
  • Home
  • About Us
    • Our Team
    • Founders
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Precision Therapies
    • Therapeutic Programs
    • QurAlis Technology
    • Therapeutic Targets
    • Biomarkers
  • News
  • Investors
  • Contact Us
    • Careers

ALS Association Statement on VITALITY-ALS Results

November 21, 2017
ALS Association Statement on VITALITY-ALS Results
Source: The ALS AssociationPublished on 2017-11-21

QurAlis is specifically focused on discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.

Sitemap

  • Home
  • About Us
  • Precision Therapies
  • News
  • Investors
  • Contact Us

Precision Therapies

  • Overview
  • Therapeutic Programs
  • QurAlis Technology
  • Therapeutic Targets
  • Biomarkers

Contact Us

QurAlis Corporation
700 Main Street, North
Cambridge, MA 02139, USA
(+1) 617.682.6015

© 2018 QurAlis LLC | Digital Solutions Provided by Zero Gravity Marketing